Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
14,220
-650 (-4.37%)
Oct 12, 2026, 3:30 PM KST

Onconic Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
645,699869,777176,537---
Market Cap Growth
-31.31%392.69%----
Enterprise Value
583,354816,363152,373---
Last Close Price
14220.0019550.004085.00---

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
26.9155.11----
PS Ratio
7.8616.2911.90---
PB Ratio
7.5312.073.15---
P/TBV Ratio
7.5312.073.15---
P/FCF Ratio
39.1678.41----
P/OCF Ratio
38.4276.33----

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
7.1015.2910.27---
EV/EBITDA Ratio
32.6462.09----
EV/EBIT Ratio
33.7164.69----
EV/FCF Ratio
35.3873.60----

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.000.01-0.060.00-0.02
Debt / EBITDA Ratio
0.020.01-0.13--
Debt / FCF Ratio
0.020.01-0.12--
Net Debt / Equity Ratio
-0.73-0.73-0.765.051.242.34
Net Debt / EBITDA Ratio
-3.49-4.009.82-11.051.852.25
Net Debt / FCF Ratio
-3.78-4.745.35-9.971.562.11
Asset Turnover
1.050.780.300.620.00-
Quick Ratio
11.3217.4810.610.711.0636.08
Current Ratio
11.3917.6210.940.711.0636.10
Return on Equity (ROE)
33.51%24.65%-32.29%---
Return on Assets (ROA)
13.81%11.55%-6.09%4.07%-36.85%-
Return on Capital Employed (ROCE)
20.10%17.50%-8.50%-39.40%-343.70%-44.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
3.76%1.81%-4.58%---
FCF Yield
2.55%1.27%-4.52%---
Buyback Yield / Dilution
-11.48%-38.72%-41.46%0.00%-0.94%-